GlassScriptPhysician profile
Pablo Delgado
NPI 1356347827
$639.27
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $79.27.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $366.97 | 2019-2020 | |
| Allergan, INC. | $56.20 | 2019-2020 | |
| Duchesnay USA Incorporated | $40.14 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.17 | 2019 | |
| Coopersurgical, INC. | $33.19 | 2019-2020 | |
| Hologic Sales and Service, LLC | $31.96 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.48 | 2019 | |
| Coloplast Corp | $16.88 | 2019 | |
| Therapeuticsmd, INC. | $15.60 | 2019 | |
| Lupin INC. | $14.95 | 2019 | |
| Merck Sharp & Dohme LLC | $11.73 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Delgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.